Aldosterone News and Research

RSS
Aldosterone is a steroid hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps control the balance of water and salts in the kidney by keeping sodium in and releasing potassium from the body. Too much aldosterone can cause high blood pressure and a build-up of fluid in body tissues. Aldosterone is a type of mineralocorticoid hormone.
U-M Professor to review data from three prominent studies on heart failure

U-M Professor to review data from three prominent studies on heart failure

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

Individuals without ubiquitin ligase Nedd4L more likely to develop CF

UNC researchers develop technique that can observe cellular intricacies of CF

UNC researchers develop technique that can observe cellular intricacies of CF

High dietary salt intake and obesity together trigger abnormal activation of cellular protein

High dietary salt intake and obesity together trigger abnormal activation of cellular protein

Scientists identify 28 blood pressure-associated genetic variants

Scientists identify 28 blood pressure-associated genetic variants

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

APS sponsors 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels

Conference to focus on connection between fluid balance and hypertension

Conference to focus on connection between fluid balance and hypertension

Sorbent expands $36M Series B financing

Sorbent expands $36M Series B financing

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Study finds high prevalence of diabetic kidney disease in the U.S.

Study finds high prevalence of diabetic kidney disease in the U.S.

Key heart failure therapies could prevent nearly 68,000 deaths each year

Key heart failure therapies could prevent nearly 68,000 deaths each year

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

Eplerenone reduces new onset atrial fibrillation and flutter in patients with class 2 heart failure

Study: Only 15% of heart failure patients with spinal fractures are being treated for osteoporosis

Study: Only 15% of heart failure patients with spinal fractures are being treated for osteoporosis

Confusing research on salt and heart: Study

Confusing research on salt and heart: Study

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Adherence to guideline-related therapies can reduce heart failure patients' mortality rate

Adherence to guideline-related therapies can reduce heart failure patients' mortality rate

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Study finds increased risk of VTE during first year of combination oral contraceptive usage

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

IQWiG publishes results of search update for evidence-based clinical practice guidelines on CHD

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.